NasdaqGS - Nasdaq Real Time Price USD
Relmada Therapeutics, Inc. (RLMD)
At close: November 6 at 4:00 PM EST
After hours: November 6 at 4:00 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Sergio Traversa M.B.A., Pharm.D. | CEO & Director | 1.79M | -- | 1960 |
| Mr. Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer | 1.01M | -- | 1964 |
| Mr. Charles S. Ence CPA, M.B.A. | Chief Accounting & Compliance Officer | 995.03k | -- | 1965 |
| Dr. Paolo Manfredi M.D., Ph.D. | Chief Scientific Officer | -- | -- | 1962 |
| Ms. Gina DiGuglielmo | VP & Head of Clinical Operations | -- | -- | -- |
| Dr. Marco Pappagallo M.D. | Chief Clinical Officer | -- | -- | 1959 |
| Mr. John Hixon | Head of Commercial | -- | -- | -- |
| Dr. Andrew Cutler | Senior Clinical Development Advisor | -- | -- | -- |
| Dr. Richard M. Mangano | Consultant | -- | -- | 1950 |
Relmada Therapeutics, Inc.
2222 Ponce de Leon Boulevard
Floor 3
Coral Gables, FL 33134
United States
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 20
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Corporate Governance
Relmada Therapeutics, Inc.’s ISS Governance QualityScore as of November 1, 2024 is 8. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 4; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 7, 2024 at 9:00 PM UTC
Relmada Therapeutics, Inc. Earnings Date
Recent Events
September 11, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
Related Tickers
VANI Vivani Medical, Inc.
1.2600
0.00%
CLYM Climb Bio Inc
3.6500
+0.83%
MDNAF Medicenna Therapeutics Corp.
1.7210
+1.24%
2VSA.F Verastem, Inc.
3.5000
+0.57%
SLDB Solid Biosciences Inc.
6.14
+3.37%
GOSS Gossamer Bio, Inc.
0.8872
+1.11%
ALGS Aligos Therapeutics, Inc.
9.35
-4.88%
GBIO Generation Bio Co.
2.4000
+9.59%
GHRS GH Research PLC
8.72
+8.59%
NVCT Nuvectis Pharma, Inc.
8.15
+9.69%